History | Fremanezumab for preventing migraine | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 167 KB)

Published:

02 February 2022

Final draft guidance

Final draft guidance
Final appraisal document (PDF 351 KB)

Published:

16 December 2021
Public committee slides (PDF 598 KB)

Published:

16 December 2021
Committee papers (PDF 663 KB)

Published:

16 December 2021

Final draft guidance: TA631

Final draft guidance: TA631
Committee papers (PDF 2.95 MB)

Published:

12 March 2020
Final appraisal document (PDF 383 KB)

Published:

12 March 2020
Public committee slides (PDF 1.03 MB)

Published:

12 March 2020

Draft guidance: TA631

Draft guidance: TA631
Appraisal consultation document (PDF version) (PDF 365 KB)

Published:

15 November 2019
Committee papers (PDF 3.9 MB)

Published:

15 November 2019
Public committee slides (PDF 839 KB)

Published:

15 November 2019

Invitation to participate

Final scope (PDF 224 KB)

Published:

24 October 2018
Draft scope and provisional stakeholder list comments table (post-referral) (PDF 601 KB)

Published:

24 October 2018
Final stakeholder list (PDF 255 KB)

Published:

24 October 2018

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: TA631

Draft scope post referral (PDF 318 KB)

Published:

04 April 2018
Draft matrix post referral (PDF 255 KB)

Published:

04 April 2018